COMMUNIQUÉS West-GlobeNewswire

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
07/05/2025
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of [...]
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
07/05/2025
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers [...]
Best Probiotic For Women: Top Strains for Gut Health, Vaginal health & Constipation - Women Over 40,50,60 - Bioma
07/05/2025
Birštonas, May 07, 2025 (GLOBE NEWSWIRE) -- In this health-conscious era, choosing a good probiotic for women is no longer a supplement option—it's a lifestyle choice for women's health, digestion, and well-being; with [...]
The Best Place to Buy SARMs Online and OTC: Top SARM Brand & Company for Muscle Growth & Fat Loss - Safe Legal SARMS for Sale - CrazyBulk
07/05/2025
New York City, May 07, 2025 (GLOBE NEWSWIRE) -- The best place to buy SARMs is presented by CrazyBulk SARMs are the hottest trend in bodybuilding right now. Bodybuilders, weightlifters, and athletes everywhere are [...]
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
07/05/2025
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of [...]
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
07/05/2025
VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria
07/05/2025
-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) -- BTK inhibition through the SH2 domain results in greater selectivity as [...]
VALNEVA Declaration of shares and voting rights: April 30, 2025
07/05/2025
VALNEVA Declaration of shares and voting rights April 30, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
VALNEVA Déclaration d’actions et de droits de vote : 30 avril 2025
07/05/2025
VALNEVA Déclaration d’actions et de droits de vote 30 avril 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 rue [...]
Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
07/05/2025
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 7 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company [...]
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
07/05/2025
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose [...]
Valneva fait un point suite à l'annonce de l'agence européenne des médicaments sur l'utilisation d'IXCHIQ® chez les personnes âgées
07/05/2025
Saint Herblain (France), le 07 mai 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) a entamé une revue [...]
Minister of Education announces CPR, AED, and Opioid Overdose Response Training now mandatory part of the provincial curriculum
07/05/2025
Prince Edward Island students now learning how to save lives CHARLOTTETOWN, Prince Edward Island, May 07, 2025 (GLOBE NEWSWIRE) -- The Advanced Coronary Treatment (ACT) Foundation joined the Government of Prince Edward [...]
Le ministre de l'Éducation annonce que la formation en RCR, DEA et en intervention en cas de surdose d'opioïdes sera désormais obligatoire dans le programme scolaire provincial
07/05/2025
Des élèves de l’Île-du-Prince-Édouard apprennent maintenant à sauver des vies CHARLOTTETOWN, Île-du-Prince-Édouard, 07 mai 2025 (GLOBE NEWSWIRE) -- La Fondation Advanced Coronary Treatment (ACT) s’est jointe au [...]
Continued growth in revenue and operating profit
07/05/2025
Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9 million in the year- [...]
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
07/05/2025
Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy 66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global [...]
Scenic Biotech Announces Nature Publication on the Discovery of Drug Target PLA2G15, a Modifier in Lysosomal Disease
07/05/2025
In collaboration with a Stanford University research team, Scenic Biotech identified and characterized PLA2G15 as a novel target in lysosomal storage diseases Amsterdam, the Netherlands, May 07, 2025 – Scenic Biotech , [...]
Virbac : Declaration of the number of shares and voting rights 04/2025
07/05/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 04/2025
07/05/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]

Pages